Last reviewed · How we verify

Syndeio Biosciences, Inc — Portfolio Competitive Intelligence Brief

Syndeio Biosciences, Inc pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Chiesi Farmaceutici S.p.A. · 1 shared drug class
  2. Chong Kun Dang Pharmaceutical · 1 shared drug class
  3. Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
  4. Mylan Inc. · 1 shared drug class
  5. Pfizer · 1 shared drug class
  6. Takeda · 1 shared drug class
  7. Teva Branded Pharmaceutical Products R&D, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Syndeio Biosciences, Inc:

Cite this brief

Drug Landscape (2026). Syndeio Biosciences, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/syndeio-biosciences-inc. Accessed 2026-05-16.

Related